AGE1

Company.com is available for acquisition. We are accepting serious, bonafide offers only.

Aerska is a company focused on developing RNA medicines specifically targeting brain diseases. Founded by an experienced leader in oligonucleotide therapeutics, Aerska aims to create innovative treatments through partnerships with biotech, academia, and research institutions.

Conception is pioneering a stem cell technology known as in-vitro gametogenesis (IVG) to transform stem cells into viable human eggs. This innovative approach aims to assist families facing infertility, enable older couples to have biological children, and potentially reduce the risk of genetic diseases in future generations.

Fauna Bio is a biotechnology company focused on leveraging the unique adaptations of animals to unlock breakthroughs in human health. They partner with pharmaceutical and biotech companies to explore innovative approaches to difficult disease areas through the lens of human genomics.

General Proximity is a biotech company pioneering next-gen proximity medicines, focusing on undruggable targets using its OmniTAC platform.

Gordian Biotechnology is a gene therapy testing platform that focuses on in vivo drug discovery and development. Founded in 2018, the company is headquartered in San Francisco, California, and aims to accelerate the drug testing process.

Loyalfordogs is a veterinary medicine company focused on extending dogs' lifespans and healthspans through clinical-stage drug development.

Navitor Pharmaceuticals focuses on developing treatments targeting mTORC1 to modulate cellular function, with a pipeline including NV-5138, a direct mTORC1 activator.

Reservoir Neuroscience develops therapeutics to heal the blood-brain barrier.

Science Corporation is a clinical-stage medical technology company focused on brain-computer interfaces and neural engineering. It develops advanced hardware for research and medical applications, aiming to restore quality of life for those with debilitating conditions.

Skeletalis Bio is focused on developing targeted therapies for osteoporosis treatment, utilizing a small-molecule platform called OASIS to enhance bone health and rebuild skeletal resilience.

Springdiscovery is a company focused on developing technology to accelerate drug discovery, specializing in inflammasome biology. The company aims to provide scientists with advanced tools for research, effectively enhancing their capabilities in the drug discovery process.

The first specialist venture capital fund created explicitly to invest only in companies extending human healthy lifespan and treating aging itself as a disease, founded and led by Laura Deming who began aging research at 12 and became one of the youngest fund managers in the U.S. Despite being a small seed/Series A vehicle, its companies have collectively raised over $1B and produced multiple IPOs, demonstrating that a focused aging thesis could generate mainstream biotech outcomes and helping legitimize longevity biotech as an investable category.

Early-stage investor specializing in companies that help people live longer and better, offering complementary expertise via two funds: delightful moments and the science of health and happiness.

Founded by Bryan Johnson, invests in platforms and enabling technologies supporting inventors and scientists building programmable-biology solutions to rewrite life's operating systems and benefit humanity. OS Fund believes biology is programmable, and invests in platforms and enabling technologies (i.e. Ginkgo Bioworks).

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.